NRAS mutation

Activating NRAS mutations detected by sequencing or PCR; used as a predictive marker in colorectal cancer (anti-EGFR antibodies) and studied in melanoma.

CI-BIO-00000017NRAS graph →NCIt C41381 Tumor-agnostic · 4 approval rows

Also calledNRAS-mutant · NRAS-mutated

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (13)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	17	16	1	—	1 / 6 / 8 / 2 / 0
Melanoma	15	12	2	1	0 / 6 / 6 / 3 / 0
Cutaneous Melanoma	9	9	—	—

Derived

Drugs with predictive evidence (20)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	14	—	14	A	0 / 13	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	8	8	—	B	7 / 0	Cutaneous Melanoma, Melanoma, Neuroblastoma, Solid Neoplasm
TrametinibSmall Molecule	6	6	—	B	5 / 0	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma, Malignant Neoplasm, Malignant Ovarian Serous Tumor +1
SelumetinibSmall Molecule	6	6	—	B	4 / 0	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
BelvarafenibSmall Molecule	5	5	—	C	5 / 0	Acral Lentiginous Melanoma, Melanoma, Mucosal Melanoma
Chemotherapy	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	4	—	4	C	0 / 4	Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	3	—	3	B	0 / 3	Cutaneous Melanoma, Melanoma
PanitumumabMonoclonal Antibody	2	—	2	A	0 / 2	Malignant Colorectal Neoplasm
TemozolomideSmall Molecule	2	2	—	C	2 / 0	Melanoma
AmuvatinibSmall Molecule	1	1	—	D	1 / 0	Cutaneous Melanoma
DabrafenibSmall Molecule	1	—	1	B	0 / 1	Melanoma
DactolisibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	1	1	—	B	1 / 0	Cutaneous Melanoma
EverolimusSmall Molecule	1	1	—	D	1 / 0	Neuroblastoma
MetforminSmall Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
OmipalisibSmall Molecule	1	1	—	D	1 / 0	Melanoma
RibociclibSmall Molecule	1	1	—	B	1 / 0	Cutaneous Melanoma
TanespimycinSmall Molecule	1	1	—	C	1 / 0	Melanoma
MEK Inhibitor RO4987655	1	—	1	C	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (47)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–47 of 47 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NRAS G13R3
Belvarafenib	Acral Lentiginous Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13214 A patient with acral melanoma harboring NRAS G13R received belvarafenib monotherapy after four prior lines of systemic therapy and achieved stable disease as the best RECIST response. The patient rece… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID2204 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Panitumumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID3842 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q61K8
Belvarafenib	Acral Lentiginous Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13218 A patient with acral melanoma harboring NRAS Q61K received belvarafenib as first-line therapy for metastatic disease after progression on adjuvant pembrolizumab and achieved stable disease as the best… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
Selumetinib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1475 Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acqui… (full text at CIViC) PMID 22194965 · Atefi et al., 2011 · Open in CIViC	civic
Vemurafenib	Cutaneous MelanomaALIAS	Predictive
NRAS Mutation14
Amuvatinib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	1	accepted	EID1476 Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growt… (full text at CIViC) PMID 24950457 · Fedorenko et al., 2014 · Open in CIViC	civic
Binimetinib	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1472 Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed). PMID 23414587 · Ascierto et al., 2013 · Open in CIViC	civic
〃	Cutaneous MelanomaALIAS
NRAS Q615
Binimetinib	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1226 Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation. 71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9… (full text at CIViC) PMID 23414587 · Ascierto et al., 2013 · Open in CIViC	civic
Selumetinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID1473 Phase 1 trial in 57 patients with advanced cancers treated with selumetinib. 4 melanoma patients had NRAS Q61 mutations. One patient with NRAS mutation had 70% tumor shrinkage after three cycles of se… (full text at CIViC) PMID 18390968 · Adjei et al., 2008 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER
NRAS G12D2
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	—	accepted	EID3693 In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC	civic
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID2002 One patient participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G12D and was wild type for KRAS, PIK3CA, and… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q179*1
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	—	accepted	EID4785 In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC	civic
NRAS Q61R3
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID2184 Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61R and were wildtype for KRAS, BRAF and P… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Belvarafenib	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13220 A patient with melanoma harboring NRAS Q61R received belvarafenib monotherapy after one prior line of systemic therapy and achieved stable disease as the best RECIST response. At the October 2023 data… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
Temozolomide	Melanoma	Predictive	C	Supports Sensitivity Response
NRAS G12C1
Cetuximab + ChemotherapyCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID3845 Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS G12C and were wild type for KRAS, PIK3CA, an… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q61L3
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID2181 Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61L and were wildtype for KRAS, BRAF and PI… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Temozolomide	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID22 In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months. PMID 21576590 · Soon et al., 2011 · Open in CIViC	civic
Belvarafenib	Mucosal Melanoma	Predictive	C	Supports Sensitivity Response
NRAS Q61H1
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID3690 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS Q61H was wildtype for KRAS, BRAF and PIK3CA.… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Mutation + NRAS MutationHRAS BRAF NF1 KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11681 In this phase II study of the arm E of the NCI-COG pediatric MATCH trial, 20 patients (median age: 14) were treated with Selumetinib. High-grade glioma (n=7) and rhabdomyosarcoma (n=7) were the most c… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Inactivating Mutation + NRAS MutationHRAS NF1 BRAF KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11696 In this Phase II study, 20 patients harboring activating RAS gene mutations (KRAS = 8, NRAS = 3. HRAS = 1), BRAF V600E mutations, and NF1 inactivating mutations (n=7) were treated with Selumetinib. No… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
NRAS G12A1
Belvarafenib	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13153 A patient with melanoma harboring NRAS G12A received belvarafenib monotherapy after two prior lines of systemic therapy and achieved a partial response as the best RECIST response. Belvarafenib treatm… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
NRAS Gain1
Binimetinib	Melanoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID6899 In melanoma preclinical models, increased NRAS expression enhanced sensitivity to binimetinib in NRAS-copy-normal A875 cells, whereas NRAS knockdown decreased binimetinib sensitivity in NRAS-gain WM26… (full text at CIViC) PMID 29245078 · Yan et al., 2018 · Open in CIViC	civic
NRAS G13D1
Tanespimycin	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID21 Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mu… (full text at CIViC) PMID 18375819 · Banerji et al., 2008 · Open in CIViC	civic
BRAF V600E + NRAS MutationBRAF NRAS1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	2	accepted	EID6263 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (333)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Dabrafenib	US FDA	Tumor-agnostic	the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated	approved	Mar 16, 2023	openfda
Dabrafenib	US FDA	Tumor-agnostic	the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated	approved

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (349)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 188 recruiting · 62 active phase 3 · 1,723 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 101–150 of 349 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01989585	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	active not recruiting	Phase 1 / Phase 2	75	National Cancer Institute (NCI)NIH	1	Aug 11, 2026	clinicaltrials
NCT03392246	A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer	active not recruiting	Phase 2	25	Dana-Farber Cancer InstituteOTHER	1	Aug 11, 2026	clinicaltrials
NCT04526782	ENCOrafenib With Binimetinib in bRAF NSCLC(ENCO-BRAF)	active not recruiting	Phase 2	119	Intergroupe Francophone de Cancerologie ThoraciqueOTHER	1	Aug 11, 2026	clinicaltrials
NCT04685135	Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation(KRYSTAL-12)	active not recruiting	Phase 3	453	Mirati Therapeutics Inc.INDUSTRY	24	Aug 11, 2026	clinicaltrials
NCT02231775	Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation	active not recruiting	Phase 2	58	M.D. Anderson Cancer CenterOTHER	1	Aug 10, 2026	clinicaltrials
NCT07668752	A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation	recruiting	Phase 3	300	Genfleet Therapeutics (Shanghai) Inc.INDUSTRY	1	Aug 10, 2026	clinicaltrials
NCT04151940	PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer	recruiting	N/A	80	University of WashingtonOTHER	1	Aug 6, 2026	clinicaltrials
NCT05176483	Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002)	recruiting	Phase 1	1,394	ExelixisINDUSTRY	13	Aug 5, 2026	clinicaltrials
NCT06358430	Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)	active not recruiting	Phase 1	10	M.D. Anderson Cancer CenterOTHER	1	Aug 4, 2026	clinicaltrials
NCT07397338	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	recruiting	Phase 1 / Phase 2	370	Revolution Medicines, Inc.INDUSTRY	1	Aug 3, 2026	clinicaltrials
NCT03091257	A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma	active not recruiting	Phase 1	30	Massachusetts General HospitalOTHER	1	Jul 31, 2026	clinicaltrials
NCT05217446	A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer(SEAMARK)	active not recruiting	Phase 2	108	PfizerINDUSTRY	15	Jul 31, 2026	clinicaltrials
NCT05382559	A Study of ASP3082 in Adults With Advanced Solid Tumors	recruiting	Phase 1	681	Astellas Pharma IncINDUSTRY	7	Jul 31, 2026	clinicaltrials
NCT05691491	Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness	recruiting	Phase 1 / Phase 2	42	National Cancer Institute (NCI)NIH	1	Jul 31, 2026	clinicaltrials
NCT04337177	Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors	active not recruiting	Phase 1	20	Valent Technologies, LLCINDUSTRY	1	Jul 30, 2026	clinicaltrials
NCT04657068	A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors	recruiting	Phase 1 / Phase 2	542	Artios Pharma LtdINDUSTRY	4	Jul 30, 2026	clinicaltrials
NCT07669415	A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors	recruiting	Phase 2	108	LaNova Medicines LimitedINDUSTRY	1	Jul 30, 2026	clinicaltrials
NCT02486718	Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]	active not recruiting	Phase 3	1,280	Hoffmann-La RocheINDUSTRY	21	Jul 29, 2026	clinicaltrials
NCT03785249	Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1	active not recruiting	Phase 1 / Phase 2	731	Mirati Therapeutics Inc.INDUSTRY	2	Jul 29, 2026	clinicaltrials
NCT06764771	A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors	recruiting	Phase 1	437	Bristol-Myers SquibbINDUSTRY	3	Jul 29, 2026	clinicaltrials
NCT07411599	Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")	recruiting	Phase 1 / Phase 2	28	M.D. Anderson Cancer CenterOTHER	1	Jul 28, 2026	clinicaltrials
NCT06745908	Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In	recruiting	Phase 3	507	ImmunityBio, Inc.INDUSTRY	3	Jul 27, 2026	clinicaltrials
NCT03155620	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	active not recruiting	Phase 2	1,377	National Cancer Institute (NCI)NIH	4	Jul 24, 2026	clinicaltrials
NCT03768063	A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study(IMbrella B)	active not recruiting	Phase 3	1,000	Hoffmann-La RocheINDUSTRY	24	Jul 24, 2026	clinicaltrials
NCT04776655	Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB(LIBImAb)	active not recruiting	Phase 3	280	Azienda USL Reggio Emilia - IRCCSOTHER_GOV	1	Jul 24, 2026	clinicaltrials
NCT07094893	Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status(ARIEL-ENGIC)	not yet recruiting	Phase 4	280	Gruppo Oncologico del Nord-OvestOTHER	0	Jul 24, 2026	clinicaltrials
NCT07098299	Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies	recruiting	Phase 1	60	Barbara Ann Karmanos Cancer InstituteOTHER	1	Jul 24, 2026	clinicaltrials
NCT05719558	A Study of ASP1002 in Adults for Treatment of Solid Tumors	recruiting	Phase 1	798	Astellas Pharma Global Development, Inc.INDUSTRY	1	Jul 23, 2026	clinicaltrials
NCT05836324	A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors	recruiting	Phase 1	570	Incyte CorporationINDUSTRY	9	Jul 23, 2026	clinicaltrials
NCT06012435	A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer	active not recruiting	Phase 3	762	Seagen, a wholly owned subsidiary of PfizerINDUSTRY	25	Jul 23, 2026	clinicaltrials
NCT06472245	Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor(ARTEMIA)	recruiting	Phase 3	363	OSE ImmunotherapeuticsINDUSTRY	14	Jul 23, 2026	clinicaltrials
NCT06724042	Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors	not yet recruiting	Phase 1	159	InSilico Medicine Hong Kong LimitedINDUSTRY	0	Jul 23, 2026	clinicaltrials
NCT06974110	Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors	recruiting	Phase 1	132	MOMA TherapeuticsINDUSTRY	2	Jul 23, 2026	clinicaltrials
NCT07172919	A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation	recruiting	Phase 2	14	AmgenINDUSTRY	9	Jul 23, 2026	clinicaltrials
NCT05142189	Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer(LuCa-MERIT-1)	recruiting	Phase 1	320	BioNTech SEINDUSTRY	8	Jul 22, 2026	clinicaltrials
NCT06179160	A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	recruiting	Phase 1	710	Incyte CorporationINDUSTRY	8	Jul 22, 2026	clinicaltrials
NCT06721689	PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors(PEEL-224)	recruiting	Phase 1 / Phase 2	59	Theodore LaetschOTHER	1	Jul 22, 2026	clinicaltrials
NCT07318805	A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors	recruiting	Phase 1	260	PfizerINDUSTRY	1	Jul 22, 2026	clinicaltrials
NCT01933932	Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC(SELECT-1)	active not recruiting	Phase 3	510	AstraZenecaINDUSTRY	26	Jul 21, 2026	clinicaltrials
NCT05238922	Study of INCB123667 in Subjects With Advanced Solid Tumors	active not recruiting	Phase 1	291	Incyte CorporationINDUSTRY	8	Jul 21, 2026	clinicaltrials
NCT06450041	NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial	recruiting	Phase 2	62	New Approaches to Neuroblastoma Therapy ConsortiumOTHER	1	Jul 20, 2026	clinicaltrials
NCT06607185	A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors	active not recruiting	Phase 1	750	Eli Lilly and CompanyINDUSTRY	8	Jul 20, 2026	clinicaltrials
NCT04439318	Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)	active not recruiting	Phase 2	50	National Cancer Institute (NCI)NIH	1	Jul 17, 2026	clinicaltrials
NCT04439357	Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)	active not recruiting	Phase 2	4	National Cancer Institute (NCI)NIH	1	Jul 17, 2026	clinicaltrials
NCT01087554	Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer	active not recruiting	Phase 1	249	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	Phase 2	59	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	Phase 1 / Phase 2	37	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT03599752	Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases	active not recruiting	Phase 2	40	M.D. Anderson Cancer CenterOTHER	2	Jul 16, 2026	clinicaltrials
NCT06942039	Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation	recruiting	Early Phase 1	15	C17 CouncilOTHER	1	Jul 14, 2026	clinicaltrials
NCT07027748	Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma	recruiting	Phase 1	18	Steven DuBois, MDOTHER	1	Jul 14, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (13)

Drugs with predictive evidence (20)

Predictive evidence items (47)

Approvals mentioning the linked drugs (333)

Active trials (349)

Linked publications (37)